Hims & Hers Health stock falls as FDA ends drug shortage

Investing.com -- Shares of Hims & Hers Health, Inc. (NYSE: HIMS) dropped by 18% following the announcement from the U.S. Food and Drug Administration (FDA) that the shortage of Novo Nordisk (NYSE:NVO) A/S’s weight-loss drug has ended. This regulatory update is expected to impact the availability and sales of cheaper, compounded versions of the drug that have been provided by telehealth companies like Hims & Hers Health.

The FDA’s statement indicated that Novo Nordisk can now satisfy nationwide demand for its weight-loss and diabetes medications, Ozempic and Wegovy. During the period of shortage, compounding pharmacies were permitted to produce exact replicas of these brand-name drugs, which were then sold at lower prices through telehealth platforms since 2022. With the shortage resolved, these pharmacies no longer have the authorization to compound identical versions of the medications.

While compounding pharmacies may continue to create alternative formulations of the drugs by adjusting doses or adding different ingredients, the decision is a blow to companies like Hims & Hers Health that benefited from the ability to offer these compounds.

Despite the recent downturn, Hims & Hers Health’s stock had seen a significant increase of 43% in the past five days prior to the FDA’s announcement. The end of the drug shortage and subsequent regulatory implications have now pared these gains, reflecting the market’s response to the new challenges facing the company’s product offerings.

As investors assess the impact of the FDA’s decision on Hims & Hers Health’s business model, the company’s stock movement today is a direct reflection of the changing landscape in the pharmaceutical and telehealth markets. The news underscores the volatility that can arise from regulatory changes and their immediate effect on companies operating within these sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.